Proactive Investors Interview – Algernon Pharmaceutical’s Preclinical Study of DMT for Stroke Confirms Growth of Neurons by 40%
Proactive Investors Interview – Algernon Pharmaceutical’s Preclinical Study of DMT for Stroke Confirms Growth of Neurons by 40%
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has confirmed in a preclinical study, that DMT increased the growth of cortical neurons by 40% with statistical significance in one arm of the study and was achieved with a sub hallucinogenic dose.
Mr. Moreau explains to Proactive this initial stage was designed to provide information on the dose and duration of infusion needed to achieve maximal cortical neurite outgrowth as well as the underlying mechanism of the drug’s action. The next stage will be to look at treatment time and should be completed at the end of October 2021.
